Literature DB >> 24476440

Albumin-bound paclitaxel plus gemcitabine in pancreatic cancer.

Ranjit K Sahoo, Lalit Kumar.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24476440     DOI： 10.1056/NEJMc1314761

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  6 in total

1.  Porphyrin-lipid stabilized paclitaxel nanoemulsion for combined photodynamic therapy and chemotherapy.

Authors:  Enling Chang; Jiachuan Bu; Lili Ding; Jenny W H Lou; Michael S Valic; Miffy H Y Cheng; Véronique Rosilio; Juan Chen; Gang Zheng
Journal:  J Nanobiotechnology       Date:  2021-05-25       Impact factor: 10.435

2.  Caveolae-Mediated Endocytosis Is Critical for Albumin Cellular Uptake and Response to Albumin-Bound Chemotherapy.

Authors:  Moumita Chatterjee; Edgar Ben-Josef; Ryan Robb; Marall Vedaie; Star Seum; Krishnan Thirumoorthy; Kamalakannan Palanichamy; Matthew Harbrecht; Arnab Chakravarti; Terence M Williams
Journal:  Cancer Res       Date:  2017-09-18       Impact factor: 12.701

Review 3.  Quantitative phenotypic and pathway profiling guides rational drug combination strategies.

Authors:  John C Dawson; Neil O Carragher
Journal:  Front Pharmacol       Date:  2014-05-28       Impact factor: 5.810

4.  Atorvastatin (Lipitor) attenuates the effects of aspirin on pancreatic cancerogenesis and the chemotherapeutic efficacy of gemcitabine on pancreatic cancer by promoting M2 polarized tumor associated macrophages.

Authors:  Qiaofei Liu; Yuan Li; Zheyu Niu; Yi Zong; Mengyi Wang; Lutian Yao; Zhaohui Lu; Quan Liao; Yupei Zhao
Journal:  J Exp Clin Cancer Res       Date:  2016-02-16

5.  Pancreatic ductal adenocarcinoma: Role of chemotherapy & future perspectives.

Authors:  Akash Tiwari; Lalit Kumar
Journal:  Indian J Med Res       Date:  2018-09       Impact factor: 2.375

Review 6.  Combination therapeutics in complex diseases.

Authors:  Bing He; Cheng Lu; Guang Zheng; Xiaojuan He; Maolin Wang; Gao Chen; Ge Zhang; Aiping Lu
Journal:  J Cell Mol Med       Date:  2016-09-07       Impact factor: 5.310
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.